Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 13-16, 2025. Richard A. Miller, M.D., the company's president and chief executive officer, will engage in one-on-one investor meetings and deliver a corporate overview presentation.
The presentation is scheduled for Wednesday, January 15, 2025, at 2:15 pm ET / 11:15 am PT. An audio webcast will be available live and accessible for 30 days after the event through the investor relations section of Corvus's website.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare a San Francisco, prevista per il 13-16 gennaio 2025. Richard A. Miller, M.D., presidente e amministratore delegato dell'azienda, parteciperà a incontri individuali con gli investitori e presenterà una panoramica aziendale.
La presentazione è programmata per mercoledì 15 gennaio 2025, alle 14:15 ET / 11:15 PT. Una webcast audio sarà disponibile in diretta e accessibile per 30 giorni dopo l'evento attraverso la sezione delle relazioni con gli investitori del sito web di Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare en San Francisco, programada para el 13-16 de enero de 2025. Richard A. Miller, M.D., presidente y director ejecutivo de la compañía, participará en reuniones individuales con inversores y ofrecerá una presentación general de la empresa.
La presentación está programada para el miércoles 15 de enero de 2025, a las 2:15 p. m. ET / 11:15 a. m. PT. Una transmisión web en audio estará disponible en vivo y accesible por 30 días después del evento a través de la sección de relaciones con inversores del sitio web de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 샌프란시스코에서 2025년 1월 13-16일에 예정된 제43회 연례 J.P. Morgan Healthcare 컨퍼런스에 참여한다고 발표했습니다. Richard A. Miller, M.D.는 회사의 회장 겸 CEO로서 투자자와의 일대일 회의에 참여하고 기업 개요 발표를 할 예정입니다.
발표는 2025년 1월 15일 수요일 오후 2시 15분 ET / 오전 11시 15분 PT에 예정되어 있습니다. 오디오 웹캐스트는 실시간으로 제공되며, 이벤트 후 30일 동안 Corvus 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé sa participation à la 43e Conférence annuelle J.P. Morgan Healthcare à San Francisco, prévue du 13 au 16 janvier 2025. Richard A. Miller, M.D., président et directeur général de l'entreprise, participera à des réunions individuelles avec les investisseurs et fera une présentation générale de l'entreprise.
La présentation est programmée pour le mercredi 15 janvier 2025, à 14h15 ET / 11h15 PT. Un webinaire audio sera disponible en direct et accessible pendant 30 jours après l'événement dans la section relations investisseurs du site Web de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco bekannt gegeben, die vom 13. bis 16. Januar 2025 stattfinden wird. Richard A. Miller, M.D., Präsident und CEO des Unternehmens, wird an persönlichen Investorengesprächen teilnehmen und eine Unternehmensübersicht präsentieren.
Die Präsentation ist für Mittwoch, den 15. Januar 2025, um 14:15 Uhr ET / 11:15 Uhr PT geplant. Ein Audio-Webcast wird live verfügbar sein und bis 30 Tage nach der Veranstaltung über den Bereich Investor Relations der Website von Corvus zugänglich sein.
- None.
- None.
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.
An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the CRVS J.P. Morgan Conference presentation webcast be available?
What type of meetings will CRVS conduct at the J.P. Morgan Healthcare Conference 2025?
Where can investors access the CRVS J.P. Morgan Conference presentation webcast?
What are the dates for the 43rd J.P. Morgan Healthcare Conference where CRVS is presenting?
